Anavex Faces Setback in EU Alzheimer's Drug Review
Anavex Life Sciences receives negative EU opinion for blarcamesine Alzheimer's treatment but plans to request re-examination with new reviewers.
Feed↓
/ What's going on?
Filter:
LENZ Stock Plunges After Retinal Tear Case Linked to VIZZ Eye Drops
LENZ Therapeutics shares dropped 27% following reports of a retinal tear associated with VIZZ presbyopia treatment, raising investor safety concerns despite company reassurances.
Fermi Shares Crash After Losing $150M Funding Deal
Fermi's stock plummeted 35% Friday after a potential tenant terminated a $150 million funding agreement for its Texas data center project, raising concerns for the newly public company.
Oracle Delays OpenAI Data Centers to 2028 Amid Shortages
Oracle pushes back completion of massive OpenAI data centers by one year to 2028, citing labor and material shortages in $300B cloud computing deal.
Rivian Surges as Self-Driving Tech Impresses Analysts
Rivian shares surge to nearly 2-year high as analysts praise custom autonomous driving chip and affordable AI features, positioning company as potential #2 EV player in North America.
ImmunityBio Shares Jump on European Bladder Cancer Treatment Recommendation
ImmunityBio stock climbed 8.5% after European regulators recommended approval for Anktiva, a bladder cancer treatment that helped over 70% of patients in clinical trials.